Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Univentricular Heart Disease
NCT03997097Phase 3Withdrawn
- Sponsor
- CHU Montpellier
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ASP-001 in pulmonary hypertension (PH), sponsored by CHU Montpellier. Planned start Jun 2023; status: withdrawn.
02
Drugs
ASP-001
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03997097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997097.